BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 20464732)

  • 1. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes.
    Greenhalgh J; Hockenhull J; Rao N; Dundar Y; Dickson RC; Bagust A
    Cochrane Database Syst Rev; 2010 May; (5):CD004587. PubMed ID: 20464732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stents versus bare-metal stents for acute coronary syndrome.
    Feinberg J; Nielsen EE; Greenhalgh J; Hounsome J; Sethi NJ; Safi S; Gluud C; Jakobsen JC
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012481. PubMed ID: 28832903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes.
    Bakhai A; Hill RA; Dundar Y; Dickson R; Walley T
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004588. PubMed ID: 15674954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary artery stents: a rapid systematic review and economic evaluation.
    Hill R; Bagust A; Bakhai A; Dickson R; Dündar Y; Haycox A; Mujica Mota R; Reaney A; Roberts D; Williamson P; Walley T
    Health Technol Assess; 2004 Sep; 8(35):iii-iv, 1-242. PubMed ID: 15361315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting stents: a systematic review and economic evaluation.
    Hill RA; Boland A; Dickson R; Dündar Y; Haycox A; McLeod C; Mujica Mota R; Walley T; Bagust A
    Health Technol Assess; 2007 Nov; 11(46):iii, xi-221. PubMed ID: 17999841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.
    Babapulle MN; Joseph L; Bélisle P; Brophy JM; Eisenberg MJ
    Lancet; 2004 Aug 14-20; 364(9434):583-91. PubMed ID: 15313358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Valgimigli M; Frati G; Kedhi E; Smits PC; Kaiser C; Genereux P; Galatius S; Kirtane AJ; Stone GW
    J Am Coll Cardiol; 2013 Aug; 62(6):496-504. PubMed ID: 23747778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
    JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug eluting stents for the treatment of bare metal in-stent restenosis: long-term outcomes in real world practice.
    Appleby CE; Khattar RS; Morgan K; Clarke B; Curzen N; Neyses L; Fath-Ordoubadi F
    EuroIntervention; 2011 Jan; 6(6):748-53. PubMed ID: 21205600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
    Bangalore S; Amoroso N; Fusaro M; Kumar S; Feit F
    Circ Cardiovasc Interv; 2013 Aug; 6(4):378-90. PubMed ID: 23922145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Study of First-Generation Drug-Eluting Stents, Second-Generation Drug-Eluting Stents and Non-Drug Eluting Stent Methods in the Treatment of Native Vessel In-Stent Restenosis in Real-World Clinical Practice.
    Yates DJ; Savage ML; Walters DL; Raffel OC
    Heart Lung Circ; 2016 Apr; 25(4):342-51. PubMed ID: 26530435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.